Remanded (sent back)
The Board is remanding the matter for another examination to address evidence indicating the use of Fluticasone and whether it required corticosteroid use to control the Veteran's sarcoidosis condition.
The deciding factor: The Court found that the Board erred by not ensuring VA complied with the duty to assist by obtaining an adequate VA medical examination, as the March 2023 VA examiner did not address January and February 2023 VA medical notes listing Fluticasone on the active outpatient medication list.
- Claimed conditions
- Sarcoidosis with pulmonary, hepatic, and lymph node involvement
- How they argued it
- Direct service connection
- Exposure basis
- None
- Rating assigned
- None in this decision
- Decision date
- November 6, 2025
- Citation
- A25096878
Want to see how appeals like this one tend to go? Appeals like mine
We are not the VA. Veterans’ Rights is an independent resource built for veterans. We are not the U.S. Department of Veterans Affairs, not part of the government, and not endorsed by any government agency.
This is general information, not legal advice. For advice about your own situation, talk to a VA-accredited representative — many help for free.